Cargando…
Tyrosine Kinase Inhibitors-Induced Arrhythmias: From Molecular Mechanisms, Pharmacokinetics to Therapeutic Strategies
With the development of anti-tumor drugs, tyrosine kinase inhibitors (TKIs) are an indispensable part of targeted therapy. They can be superior to traditional chemotherapeutic drugs in selectivity, safety, and efficacy. However, they have been found to be associated with serious adverse effects in u...
Autores principales: | Cheng, Mengfei, Yang, Fang, Liu, Jiahui, Yang, Dan, Zhang, Shuo, Yu, Yang, Jiang, Shuai, Dong, Mei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639698/ https://www.ncbi.nlm.nih.gov/pubmed/34869670 http://dx.doi.org/10.3389/fcvm.2021.758010 |
Ejemplares similares
-
Case report: Implantable cardioverter-defibrillator implantation with optimal medical treatment for lethal ventricular arrhythmia caused by recurrent coronary artery spasm due to tyrosine kinase inhibitors
por: Jin, Jifu, et al.
Publicado: (2023) -
The two facets of receptor tyrosine kinase in cardiovascular calcification—can tyrosine kinase inhibitors benefit cardiovascular system?
por: Masbuchin, Ainun Nizar, et al.
Publicado: (2022) -
Benefits of SGLT2 inhibitors in arrhythmias
por: Gao, Jinghan, et al.
Publicado: (2022) -
Tyrosine Kinase Inhibitor Pazopanib Inhibits Platelet Procoagulant Activity in Renal Cell Carcinoma Patients
por: Tullemans, Bibian M. E., et al.
Publicado: (2018) -
Cardiovascular toxicity of tyrosine kinase inhibitors during cancer treatment: Potential involvement of TRPM7
por: Liu, Qing, et al.
Publicado: (2023)